Lucid Diagnostics (NASDAQ:LUCD – Get Free Report) and Inspire Medical Systems (NYSE:INSP – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.
Institutional and Insider Ownership
74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 94.9% of Inspire Medical Systems shares are owned by institutional investors. 4.8% of Lucid Diagnostics shares are owned by company insiders. Comparatively, 4.1% of Inspire Medical Systems shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Earnings and Valuation
This table compares Lucid Diagnostics and Inspire Medical Systems’ top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Lucid Diagnostics | $2.43 million | 17.46 | -$52.67 million | ($1.27) | -0.69 |
| Inspire Medical Systems | $624.80 million | 11.83 | -$21.15 million | ($0.74) | -329.66 |
Volatility & Risk
Lucid Diagnostics has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500. Comparatively, Inspire Medical Systems has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Lucid Diagnostics and Inspire Medical Systems, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Lucid Diagnostics | 0 | 0 | 2 | 0 | 3.00 |
| Inspire Medical Systems | 0 | 4 | 10 | 0 | 2.71 |
Lucid Diagnostics presently has a consensus target price of $2.75, indicating a potential upside of 212.96%. Inspire Medical Systems has a consensus target price of $272.20, indicating a potential upside of 11.58%. Given Lucid Diagnostics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Lucid Diagnostics is more favorable than Inspire Medical Systems.
Profitability
This table compares Lucid Diagnostics and Inspire Medical Systems’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Lucid Diagnostics | -2,169.07% | -901.79% | -121.11% |
| Inspire Medical Systems | -3.39% | -3.93% | -3.38% |
Summary
Inspire Medical Systems beats Lucid Diagnostics on 8 of the 14 factors compared between the two stocks.
About Lucid Diagnostics
Lucid Diagnostics Inc., a commercial-stage medical diagnostics technology company, focuses on patients with gastroesophageal reflux disease who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma in the United States. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. Lucid Diagnostics Inc. was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
About Inspire Medical Systems
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
Receive News & Ratings for Lucid Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lucid Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
